Provided By GlobeNewswire
Last update: Aug 30, 2024
- Based on a per-protocol interim analysis of safety and efficacy data, the Independent Data Monitoring Committee (IDMC) recommended that the trial continue without modifications
- No new safety signals observed at interim analysis
- Primary endpoint of progression free survival projected to be reached in the first half of 2025
NASDAQ:IOBT (6/12/2025, 4:30:02 PM)
1.5
0 (0%)
Find more stocks in the Stock Screener